1 billion euros is the fabulous amount paid to treat patients in Member States infected with the new type of virus.
The European Union is working to provide Member States with everything they need to treat Covid patients. 1 billion euros is the amount that Brussels officials agreed to pay to Gilead. It’s about the pharmaceutical company that makes Remdesivir.
The treatment has been shown to be effective in treating those who have severe symptoms due to the virus.
The money will be used for supply for six months. And it should be noted that the amount was agreed shortly before the publication of the final results of the largest clinical trial for the antiviral drug to treat Covid-19 disease.
1 billion euros, short-term costs for treating Europeans infected with the new virus
The agreement between the EU and Gilead took place amid the shortage of Redemsivir in EU countries, which could have hastened the decision before the final results on the efficacy of Remdesivir and its possible toxicity were published. The EU signed a contract last week with the US company that will allow 27 member states and 10 partner countries, including the UK, to order up to 500,000 series of remdesivir treatment over the next six months.
The price is huge.
For each series of treatment, the amount amounts to 2,070 euros ($ 2,440), the total amount being 1.35 billion euros, according to a person close to the situation. Despite the size of the contract, the price per treatment is in line with that paid by EU countries in a much smaller supply agreement agreed in July to treat about 30,000 patients with a series of six-dose treatment.
Under the new agreement, the European governments included in the contract will pay Gilead only when they buy doses. It is unknown at this time whether orders have already been placed.
“The EU should evaluate the results of this new WHO study to see if it is worth paying more than 2,000 euros per patient,” said Andrew Hill, a senior researcher in the Department of Pharmacology at the University of Liverpool.
Gilead did not immediately comment on whether the prices for the doses of remdesivir he sells to richer countries could change according to the results of the WHO study.